Testing a new ketamine-like drug for hard-to-treat depression
Treatments studied
Part of Mental health clinical trials.
This study tests a new experimental drug (2R,6R)-HNK, a chemical related to ketamine, given by IV infusion to see if it can help people with depression that hasn't improved with other treatments. The goal is to find a new option for people who have not found relief from standard antidepressants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have major depression and are currently in a depressive episode that has lasted at least two weeks.
- Your depression has not gotten better after trying at least one antidepressant or brain stimulation treatment.
- You are between 18 and 70 years old and are generally healthy.
- You are able to stop other talk therapy and avoid certain medications for the study period.
- You must not be pregnant or nursing, and if you can have children, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests ketamine and looks at what brain changes may explain why it helps people with major depression that hasn’t improved with usual treatments. You may be asked to stay in the hospital and complete detailed interviews, mood rating scales, and brain imaging.
This early-stage study tests how ketamine given once and then repeatedly may change brain signals and related biomarkers in people with major depression. If you’re eligible, the team will use brain imaging and assessments to see who responds and why.
This early-stage study looks at how parts of brain cells respond to ketamine in people with depression who have not improved with usual antidepressants. It may help researchers find why ketamine works for some people and not others, and who might benefit.
This study tests if intravenous ketamine can help people with treatment-resistant depression who haven't found relief from at least two other treatments. If you qualify, you'll receive ketamine infusions to see if it improves your mood.
This study compares the effectiveness of esketamine (Spravato) and another similar drug, ketamine, for adults with major depression that has not improved after trying at least two other antidepressants. It aims to find out which treatment works better.
This study looks at whether an “AMPA receptor blocker” changes how ketamine affects suicidal thoughts in people with depression that hasn’t improved with usual treatments. If you qualify, you may receive ketamine and the study medicine, while continuing your regular mental health care.
Hear when a new Suicide trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.